|Articles|December 14, 2022
PHASTAR Joins Oncology Development Program (ODP2)
Targeted program aims to identify and accelerate novel oncology innovations into commercially-attractive assets.
Advertisement
PHASTAR, has joined Lean Life Science’s Oncology Development Program (ODP2). The targeted program aims to identify and accelerate novel oncology innovations into commercially-attractive assets by offering support to academics and early-stage companies.
Read more about the program
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
Generative AI Transforms Clinical Study Report DevelopmentSeptember 16th 2025
Operational Strategies That Strengthened the NIMBLE Trial DesignSeptember 16th 2025
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Generative AI Transforms Clinical Study Report Development
2
Merck Reports Strong Phase II Results for Ifinatamab Deruxtecan in Extensive-Stage Small Cell Lung Cancer
3
Phase IV Trial Shows Daybue Demonstrates Real-World Behavioral Improvements in Rett Syndrome
4
Atom Therapeutics Launches Global Phase II Trial of Novel Anti-Inflammatory Treatment for Acute Gout Flares
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
